Green Square Capital LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 28.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,503 shares of the medical instruments supplier’s stock after selling 1,011 shares during the period. Green Square Capital LLC’s holdings in Becton, Dickinson and were worth $491,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. State Street Corp raised its holdings in shares of Becton, Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after purchasing an additional 342,873 shares during the period. Northern Trust Corp raised its holdings in shares of Becton, Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after purchasing an additional 106,966 shares during the period. Fiera Capital Corp raised its holdings in shares of Becton, Dickinson and by 7.1% in the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after purchasing an additional 183,372 shares during the period. Finally, Fundsmith LLP raised its holdings in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after purchasing an additional 5,977 shares during the period. Hedge funds and other institutional investors own 88.60% of the company’s stock.

A number of research firms recently commented on BDX. Wells Fargo & Company reaffirmed a “positive” rating and issued a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reissued a “sector perform” rating and set a $230.00 target price (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating and set a $245.00 target price on shares of Becton, Dickinson and in a report on Friday, November 3rd. Finally, Morgan Stanley boosted their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $217.08.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $218.99 on Wednesday. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton, Dickinson and Company has a 1-year low of $161.50 and a 1-year high of $229.68. The stock has a market cap of $49,769.94, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.12 EPS. equities research analysts forecast that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s payout ratio is 64.52%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-green-square-capital-llc/1761098.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with Analyst Ratings Network's FREE daily email newsletter.